Showing results (1021-1030 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|November 15, 2023
Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancerLouise Faaborg, Rikke Fredslund Andersen, Sara Wc Wen, et al.
Future Oncology (London, England)|October 26, 2023
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancerNeeraj Agarwal, Fred Saad, Arun A Azad, et al.
Future Oncology (London, England)|October 26, 2023
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphomaSarah Matarasso, Sarit Assouline
Future Oncology (London, England)|October 26, 2023
Meta-analysis of quality of life in patients with cancer treated with antibody-drug conjugates in randomized controlled trialsTianlei Qiu, Guoshuang Shen, Yuanfang Xin, et al.
Future Oncology (London, England)|October 20, 2023
Current stand on systemic therapy in localized soft tissue sarcomas: a clinician's perspectiveArchana Sasi, Sameer Rastogi
Future Oncology (London, England)|October 27, 2023
Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancerLei Zhuang, Xue Bai, Ying Chen, et al.
Future Oncology (London, England)|October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancerTae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
Future Oncology (London, England)|April 17, 2024
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world studyMuhammad Furqan, Siddharth Karanth, Ravi K Goyal, et al.
Future Oncology (London, England)|April 9, 2024
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancerValentina Guarneri, José Luís Passos Coelho, Francois P Duhoux, et al.
Future Oncology (London, England)|September 4, 2023
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanomaAlexander Cj van Akkooi, Axel Hauschild, Georgina V Long, et al.
Pageof 452